Zacks Research Analysts Boost Earnings Estimates for IOVA

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share estimates for Iovance Biotherapeutics in a research note issued on Wednesday, August 26th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.13) for the quarter, up from their previous estimate of ($0.14). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.48) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.56) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.44) EPS, Q1 2028 earnings at ($0.07) EPS, Q2 2028 earnings at ($0.02) EPS and FY2028 earnings at ($0.07) EPS.

A number of other research analysts also recently weighed in on IOVA. Robert W. Baird set a $6.00 price objective on shares of Iovance Biotherapeutics in a research report on Friday, August 7th. Citizens Jmp lifted their price target on Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Mizuho upped their price target on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Barclays raised their price objective on Iovance Biotherapeutics from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research report on Thursday, July 2nd. Seven analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $8.89.

Iovance Biotherapeutics Price Performance

IOVA opened at $8.26 on Friday. The firm has a fifty day moving average price of $5.39 and a 200 day moving average price of $4.29. Iovance Biotherapeutics has a 1 year low of $1.76 and a 1 year high of $9.36. The stock has a market cap of $3.74 billion, a P/E ratio of -11.31 and a beta of 0.71.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. The business had revenue of $198.63 million for the quarter, compared to analyst estimates of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.The business’s quarterly revenue was up 65.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.33) EPS.

Institutional Trading of Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently modified their holdings of IOVA. Granite Investment Partners LLC acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth about $29,000. Motley Fool Asset Management LLC purchased a new position in Iovance Biotherapeutics in the 4th quarter valued at about $29,000. M&T Bank Corp acquired a new stake in Iovance Biotherapeutics in the 4th quarter worth about $31,000. SBI Securities Co. Ltd. boosted its holdings in Iovance Biotherapeutics by 169.1% in the 4th quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company’s stock worth $32,000 after buying an additional 7,269 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Iovance Biotherapeutics during the 1st quarter worth approximately $34,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised to $10: Analysts increased their price target for IOVA to $10.00, implying potential upside from the stock’s $8.26 opening price and reinforcing recent positive momentum. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Several earnings estimates improved: Zacks Research raised its 2026 EPS forecast to a loss of $0.56 from $0.62, improved its third-quarter 2026 estimate to a loss of $0.13 from $0.14, and lifted longer-term estimates for the second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2028 forecast improved to a loss of $0.07 from $0.10, suggesting expectations for narrowing losses over time.
• Neutral Sentiment: Positive oncology-sector exposure: Zacks highlighted Iovance alongside other biotechnology companies as a potential beneficiary of advances in cancer care and pipeline development. The commentary supports investor interest but did not announce a new approval, trial result or partnership. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Negative Sentiment: Other forecasts were reduced: Zacks cut estimates for 2026 fourth-quarter EPS, 2027 first-, third- and fourth-quarter EPS, full-year 2027 EPS, and 2028 first-quarter EPS. The largest annual revision was for FY2027, moving to a loss of $0.44 from $0.36, highlighting continued uncertainty around the pace of profitability.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.